Literature DB >> 9531034

Importance of the FcgammaRIIa-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis.

C Bachelot-Loza1, R Saffroy, D Lasne, G Chatellier, M Aiach, F Rendu.   

Abstract

Heparin-induced thrombocytopenia (HIT) involves heparin-dependent antibodies which induce platelet activation. In the present study, we searched for a relationship between the polymorphism of the Fc receptor (FcgammaRIIa) and the development of HIT. In this purpose, all the donors were genotyped for their FcgammaRIIA and HIT patients were selected on the basis of at least one positive answer by 14C-serotonin release assay (SRA). The frequency distribution of the FcgammaRIIa polymorphism in the HIT patient group was similar to that observed in the healthy control group. Moreover, a statistical analysis taking into account our results and those of 3 previously published studies, suggested at most only a weak association between HIT and the FcgammaRIIa-131 polymorphism. Laboratory tests used to diagnose HIT rely on the activation of normal donor platelets but fail to detect every HIT positive patient. We determined the role of FcgammaRIIa-131 polymorphism on the reactivity of control platelets to HIT plasmas. When control platelet FcgammaRIIa-131 was of Arg/Arg form, only 47% of the HIT plasmas were positive by SRA, compared to 81% and 74% for His/His or His/Arg forms, respectively. We also compared the level of anti PF4/heparin antibodies in the HIT plasmas with the response obtained by SRA. The mean anti PF4/heparin antibodies level in HIT plasma was significantly lower in negative SRA than in positive tests when using control platelets from FcgammaRIIa-Arg/Arg 131 and heterozygous donors. Thus, the variability of control platelets to respond to HIT plasmas in the SRA test is related to both the FcgammaRIIa-131 polymorphism, and to the amount of anti PF4/heparin antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531034

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Laboratory testing for heparin-induced thrombocytopenia.

Authors:  T E Warkentin
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

2.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

Review 3.  Fundamental concepts in the pathobiology of heparin-induced thrombocytopenia.

Authors:  J L Januzzi; I K Jang
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

4.  Anti-miR-148a regulates platelet FcγRIIA signaling and decreases thrombosis in vivo in mice.

Authors:  Yuhang Zhou; Shaji Abraham; Pierrette Andre; Leonard C Edelstein; Chad A Shaw; Carol A Dangelmaier; Alexander Y Tsygankov; Satya P Kunapuli; Paul F Bray; Steven E McKenzie
Journal:  Blood       Date:  2015-10-29       Impact factor: 22.113

5.  Anti-vWf antibodies induce GPIbalpha and FcgammaRII mediated platelet aggregation only at low shear forces.

Authors:  M F Hoylaerts; A Viaene; C Thys; H Deckmyn; J Vermylen
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

6.  Platelet factor 4/heparin antibodies in blood bank donors.

Authors:  Marcie J Hursting; Poulomi J Pai; Julianna E McCracken; Fred Hwang; Shayela Suvarna; Yuliya Lokhnygina; Nicholas Bandarenko; Gowthami M Arepally
Journal:  Am J Clin Pathol       Date:  2010-11       Impact factor: 2.493

Review 7.  Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results.

Authors:  Gowthami M Arepally; Marcie J Hursting
Journal:  J Thromb Thrombolysis       Date:  2008-03-28       Impact factor: 2.300

Review 8.  Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.

Authors:  Valentine Minet; Jean-Michel Dogné; François Mullier
Journal:  Molecules       Date:  2017-04-11       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.